Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD): Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01037309).
- Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02240706).
- Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: primary endpoint results,…
- Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: primary endpoint results, effect estimate with confidence…
- Phase IIIndependent statistical analysis of Electrical Stimulation for Critically Ill Post-Covid-19 Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05198466).
- Phase II Dasatinib Study in Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dasatinib Study in Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00546104).
- Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01842646).
- Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG): Complete Statistical AnalysisIndependent statistical analysis of Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02024555).
- Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176605).
- Phase II Neoadjuvant in Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Neoadjuvant in Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756470).
- Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: primary endpoint results, effect estimate…
- Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab: Complete Statistical AnalysisIndependent statistical analysis of Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval,…
- Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes: primary endpoint results, effect estimate with confidence interval,…
- Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L): Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol…
- Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00434109).
- Phase II Study of TAK228 in Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAK228 in Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02727777).
- Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00824161).
- Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy: primary endpoint results,…
- Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.: primary endpoint results, effect estimate with…
- Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002): Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002): primary endpoint results,…
- Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…